Bivalent Smac Mimetics with a Diazabicyclic Core as Highly Potent Antagonists of XIAP and cIAP1/2 and Novel Anticancer Agents
Journal of Medicinal Chemistry2011Vol. 55(1), pp. 106–114
Citations Over Time
Yuefeng Peng, Haiying Sun, Jianfeng Lü, Liu Liu, Qian Cai, Rong Shen, Chao‐Yie Yang, Yi Han, Shaomeng Wang
Abstract
Nonpeptidic, bivalent Smac mimetics designed based upon monovalent Smac mimetics with a diazabicyclic core structure bind to XIAP, cIAP1, and cIAP2 with low to subnanomolar affinities and are highly effective in antagonizing XIAP in cell-free functional assays. They efficiently induce the degradation of cIAP1 and cIAP2 in cancer cells at concentrations as low as 1 nM, activate caspase-3 and -8, and cleave PARP at 3-10 nM. The most potent compounds in the series have IC(50) of 3-5 nM in inhibition of cell growth in both MDA-MB-231 and SK-OV-3 cell lines and are promising lead compounds for the development of a new class of cancer therapy.
Related Papers
- → Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP(2004)133 cited
- The regulation of caspase activity by inhibitor of apoptosis proteins(2007)
- → Smac-based antagonists of the inhibitors of apoptosis(2006)
- → Inhibitor of apoptosis protein XIAP and malignant tumor(2010)
- → Faculty Opinions recommendation of Discovery of a Potent Nonpeptidomimetic, Small-Molecule Antagonist of Cellular Inhibitor of Apoptosis Protein 1 (cIAP1) and X-Linked Inhibitor of Apoptosis Protein (XIAP).(2017)